Perrin Ross Amy, Williamson Alona, Smrtka Jennifer, Flemming Tracy Tracy, Saunders Carol, Easterling Constance, Niewoehner John, Mutschler Nicole
Department of Neurosciences, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA.
Mult Scler Int. 2013;2013:470476. doi: 10.1155/2013/470476. Epub 2013 May 26.
There is need for a brief but comprehensive objective assessment tool to help clinicians evaluate relapse symptoms in patients with multiple sclerosis (MS) and their impact on daily functioning, as well as response to treatment. The 2-part Assessing Relapse in Multiple Sclerosis (ARMS) questionnaire was developed to achieve these aims. Part 1 consists of 7 questions that evaluate relapse symptoms, impact on activities of daily living (ADL), overall functioning, and response to treatment for previous relapses. Part 2 consists of 7 questions that evaluate treatment response in terms of symptom relief, functioning, and tolerability. The ARMS questionnaire has been evaluated in 103 patients with MS. The most commonly reported relapse symptoms were numbness/tingling (67%), fatigue (58%), and leg/foot weakness (55%). Over half of patients reported that ADL or overall functioning were affected very much (47%) or severely (11%) by relapses. Prescribed treatments for relapses included intravenous and/or oral corticosteroids (87%) and adrenocorticotropic hormone (13%). Nearly half of patients reported that their symptoms were very much (33%) or completely resolved (16%) following treatment. The most commonly reported adverse events were sleep disturbance (45%), mood changes (33%), weight gain (29%), and increased appetite (26%). Systematic assessment of relapses and response to relapse treatment may help clinicians to optimize outcomes for MS patients.
需要一种简短但全面的客观评估工具，以帮助临床医生评估多发性硬化症（MS）患者的复发症状及其对日常功能的影响，以及对治疗的反应。为此开发了两部分的多发性硬化症复发评估（ARMS）问卷。第一部分由7个问题组成，评估复发症状、对日常生活活动（ADL）的影响、整体功能以及对既往复发治疗的反应。第二部分由7个问题组成，从症状缓解、功能和耐受性方面评估治疗反应。ARMS问卷已在103例MS患者中进行了评估。最常报告的复发症状是麻木/刺痛（67%）、疲劳（58%）和腿部/脚部无力（55%）。超过一半的患者报告说，复发对ADL或整体功能有非常大的影响（47%）或严重影响（11%）。复发的规定治疗包括静脉注射和/或口服皮质类固醇（87%）和促肾上腺皮质激素（13%）。近一半的患者报告说，治疗后他们的症状有很大改善（33%）或完全缓解（16%）。最常报告的不良事件是睡眠障碍（45%）、情绪变化（33%）、体重增加（29%）和食欲增加（26%）。对复发和复发治疗反应进行系统评估可能有助于临床医生优化MS患者的治疗效果。
